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KPNA2 Expression is an Independent Adverse Predictor of Biochemical Recurrence after 
Radical Prostatectomy. 
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TRANSLATIONAL RELEVANCE 
Biomarkers play an increasingly important role in clinical oncology. However, none of the 
published tissue biomarkers for prostate cancer has found its way into clinical practice. In this study 
we found karyopherin alpha 2 (KPNA2), a marker that we have demonstrated as an independent 
prognostic marker in breast cancer in recent studies, overexpressed during malignant tumor 
progression of prostate cancer. Moreover, KPNA2 expression was associated with shortened 
recurrence-free survival time in univariate and multivariate analyses in two independent patient 
cohorts treated by radical prostatectomy. The description of KPNA2 as an independent marker of 
PSA relapse in two independent cohorts of prostate cancer clearly constitutes KPNA2 expression as 
strong biomarker. This raises the possibility for a better individualized risk stratification to optimize 
therapy. Further studies have to clarify, if KPNA2 immunohistochemistry can also aid in the 
discrimination of insignificant and significant prostate cancer at the time of the positive biopsy. 
 
 
 
 
 
 
 
 
 
 American Association for Cancer Research Copyright © 2011 
 on February 3, 2011clincancerres.aacrjournals.orgDownloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on January 10, 2011; DOI:10.1158/1078-0432.CCR-10-0081
Clinical Cancer Research - Imaging & Diagnosis 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.  
Copyright © 2011 American Association for Cancer Research 
ABSTRACT 
Purpose: To analyze rates of expression of karyopherin alpha 2 (KPNA2) in different prostate 
tissues and to evaluate the prognostic properties for patients with primary prostate cancer. 
Experimental Design: Tissue microarrays containing 798 formalin-fixed, paraffin-embedded 
prostate tissue cores from two different institutes of pathology. TMAs were stained 
immunhistochemically for KPNA2 and NBS1. SiRNA technologies were used to inhibit KPNA2 
expression in vitro, and the effect of this inhibition on cellular viability was determined. Efficency 
of knock down experiments was determined by Western blot analysis. 
Results: KPNA2 expression was significantly upregulated in carcinomas of the prostate, especially 
in metastatic and castration-resistant prostate cancer samples. Positive nuclear KPNA2 
immunoreactivity was identified as a novel predictor of biochemical recurrence after radical 
prostatectomy (n=348), and was independent of the well-established predictive factors preoperative 
PSA value, Gleason score, tumor stage and surgical margin status. These results were validated by 
analyzing a second and independent prostate cancer cohort (n=330). Further, in vitro experiments 
showed that the cell proliferation and viability of PC3 cells was significantly reduced when KPNA2 
expression was inhibited. KPNA2 knockdown did not induce poly(ADP-ribose) polymerase 
(PARP) cleavage as marker for apoptosis. No significantly increased subG1 fraction could be found 
by FACS analysis.  
Conclusions: KPNA2 is a novel independent prognostic marker for disease progression after 
radical prostatectomy. This allows to identify patients who need more aggressive treatment. It can 
moreover be speculated that patients not suited for surveillance regimens might be identified at 
initial biopsy by a positive KPNA2 immunohistochemistry.  
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INTRODUCTION 
Accurate prediction of individual prostate cancer (PCa) behaviour is still difficult. The management 
of patients with localized disease largely consists of three modalities: radical prostatectomy, 
radiation therapy, and active surveillance. Although cure is achieved for the majority of patients 
receiving surgery or radiation therapy, still up to 30% of patients experience disease progression 
within ten years. In representative active surveillance studies up to 33% of cases experienced cancer 
progression (1). An improved identification of high-risk patients is highly desirable in order to 
individualize therapy.  
Conventional parameters for risk estimation are mainly based on preoperative PSA, the number of 
positive punch-biopsies, the Gleason score and possibly radiologic features. However, the 
prognostic value of these established classical markers is limited. Numerous novel molecular 
markers including MUC1, AZGP1, EZH2, E2F3, Ki67, CD10, RECK, ADAM9, HDAC2, 
ALCAM, and others have been proposed as prognostic parameters (2-10). A novel candidate 
biomarker for tumor aggressiveness is the expression of karyopherin alpha 2 (KPNA2). We 
previously identified KPNA2 overexpression as a possible prognostic marker for breast cancer on 
mRNA and protein level (11-13). Twenty-four matched pairs of invasive ductal breast cancer and 
corresponding benign breast tissue were investigated by a combination of laser microdissection and 
gene expression profiling. Further analysis by immunhistochemistry showed that nuclear KPNA2 
overexpression was significantly associated with shorter overall survival and recurrence-free 
survival. Nuclear KPNA2 expression was a highly significant, independent and adverse risk factor 
for overall survival in several independent study cohorts (11-13) .  
Since the relevance of KPNA2 expression as a marker for tumor aggressiveness in other tumor 
entities is largely unknown, we analyzed the extent of KPNA2 expression in different prostate 
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tissues, and the prognostic relevance of KPNA2 expression in patients with localized PCa receiving 
radical prostatectomy. Additionally, we analyzed the relationship of KPNA2 expression with its 
known interaction partner NBS1 (Nijmegen breakage syndrome 1). Finally, the role of KPNA2 on 
PCa proliferation and apoptosis has been analyzed, in vitro. 
 
 
MATERIALS & METHODS 
Patients and specimen characteristics. Tissue microarrays (TMAs) contained 798 formalin-fixed, 
paraffin-embedded prostate tissues and were constructed as previously described (14). Specimens 
were collected between 1993 and 2007 from the Institute of Surgical Pathology, University of 
Zurich, Switzerland, and the Institute of Pathology, University of Regensburg, Germany. The 
Zurich TMA (training set) included a series of 348 consecutive (non-selected) radical prostatectomy 
specimens, 29 hormone-refractory PCa samples, 18 lymph node metastases, 28 distant metastases 
(bone, lung, urinary bladder) and 45 benign prostatic hyperplasia samples. For the Zurich TMA, 
H&E-stained slides of all specimens were re-evaluated by two experienced pathologists (P.J.W., 
H.M.) to identify representative areas. Tumor stage and Gleason score of the Zurich cohort were 
assigned according to the International Union Against Cancer (UICC) and WHO/ISUP criteria (15). 
The Regensburg TMA contained a series of 330 consecutive (non-selected) radical prostatectomy 
specimens and was considered as testing cohort. Tumor stage and Gleason score of the Regensburg 
cohort were retrieved from the electronic database of the Institute of Pathology, University of 
Regensburg, Germany. In total, clinical follow-up data were available for 475 of 678 prostatectomy 
patients (70.1%). Median follow-up of the cohort from Zurich was 71 months (0-163), and 52 
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months (0-132) for the cohort from Regensburg (Supplemental Table 1). The study for both cohorts 
was approved by the local scientific ethics committees (approval no.: StV-Nr. 25/2007).  
Immunohistochemical assay. Consecutive 3µm sections were cut from the TMA tissue blocks. 
The expression of KPNA2 and NBS1 on the Zurich TMA and the expression of KPNA2 on the 
Regensburg TMA was analyzed immunohistochemically using the following primary antibodies: 
anti-KPNA2 (goat polyclonal, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA; no. sc-6917, 
dilution 1:100), anti-NBS1 (rabbit polyclonal, Cell Signaling Technology; no. 3002, dilution 
1:100), and anti-CXCR4 (mouse monoclonal, Invitrogen Corporation, Camarillo, CA; no. 
MHCXCR404, dilution 1:200). The ChemMate detection kit (DAKO, Glostrup, Denmark) was 
used. After antigen retrieval (microwave oven for 10 min at 250 W) immunohistochemistry was 
carried out in a NEXES immunostainer (Ventana, Tucson, AZ, USA) according to manufacturer’s 
instructions. Normal testicular parenchyma was chosen as internal positive control. For negative 
controls, the primary antibody was omitted. The specificity of the commercial KPNA2 antibody has 
been thoroughly validated in former studies (11-13), and was further tested by using the human PCa 
cell lines PC3 and LNCaP. Cells were trypsinized and embedded in paraffin as a cell pellet. Cell 
pellets were stained immunhistochemically for KPNA2 protein. Additionally, cell lines that were 
used for our in vitro experiments were characterised by analyzing the phosphatidylinositol-3-kinase 
(PI3)/AKT cascade (Supplemental Figures 1A-1F).   
Two surgical pathologist (P.J.W., G.K.) performed a blinded evaluation of the slides for KPNA2 
and NBS1 without knowledge of clinical data. Causes of non-interpretable results included lack of 
target tissue, presence of necrosis or crush artifact. Searching for cutoffs in an unbiased way is a 
major problem in immunohistochemical studies dealing with a continous readout. The median 
nuclear KPNA2 immunoreactivity in prostatectomy cases (median 0%) was chosen as cutoff. 
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Accordingly, positive nuclear KPNA2 and NBS1 immunoreactivity was defined as nuclear staining 
in at least 0.1% of target cells. In the Zurich cohort, cytoplasmic KPNA2 staining of any intensity 
was found ubiquitous in 440 of 455 (96.7%) informative cases and was not considered in 
subsequent statistical analyses. No cytoplasmic NBS1 expression could be detected in PCa samples. 
Cytoplasmic chemokine (C-X-C motif) receptor 4 (CXCR4) expression was estimated using a 
semiquantitative four-step scoring system (0 to 3+): 0, negative; 1+, weak positive; 2+, strong 
positive; 3+, very strong positive. Evaluation of the slides stained against CXCR4 was done by a 
surgical pathologist (M.M.). 
Cell lines. The PCa cell lines PC3 and LNCaP were obtained from American Type Culture 
Collection. Cells were grown in Dulbecco's Modified Eagle Medium (Invitrogen Corp., Carlsbad, 
CA, USA) with L-glutamine (Invitrogen Corp., Carlsbad, CA, USA) supplemented with 10% fetal 
calf serum, 100 units/ml penicillin, and 100 µg/mlL streptomycin. All cells were grown in a 
humidified atmosphere incubator with 5% CO2 at 37 °C. Cells were cultured for two weeks prior to 
their use in subsequent experiments.  
Reverse transfection of siRNAs. Knock down experiments were performed in triplicates in a 96 
well plate format with a total volume of 100 µl per well. Four specific KPNA2 and NBS1 siRNAs 
were pooled or used separately (final concentration 0.05 µM; accession no. SI02781051, 
SI02780631, SI00035539, SI00035525, SI02757524, SI02663570, SI00038479, SI00038493 
Qiagen, Hilden, Germany). SiRNAs were reverse transfected by using Lipofectamine 2000 
transfection reagent (Invitrogen) into PC3 and LNCaP cells according to the manufacturer’s 
instructions. Briefly, RNAi molecules were put in each well prior to transfection and combined with 
diluted Lipofectamine 2000 to form complexes in each well. Cells were washed twice with 5 mL 
phosphate buffered saline, trypsinized and added directly to the Lipofectamine 2000-RNA 
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complexes. Cells were seeded in Nunclon MicroWell plates (Nunc) at a density of 6,000 cells per 
well (in DMEM with 10% fetal calf serum and antibiotic-free). Transfection occurred while cells 
were attaching to the well bottom. All Stars negative control siRNA (Qiagen, Hilden, Germany; 
accession no. SI03650318), H2O, and All Stars Hs Cell Death siRNA (Qiagen, Hilden, Germany; 
accession no. SI04381048) were used as negative and positive controls, respectively. As an 
additional positive control, cells were treated with 5 µM staurosporine (Sigma-Aldrich Chemie 
GmbH, Buchs, Switzerland; no. S6942) to induce apoptosis twenty-four hours after reverse 
transfection. 
MTT assay. Viability of PC3 and LnCap cells was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-terazolium bromide (MTT) assay (16). After cells were incubated for 48 h, 100 µL MTT 
solution (0.1 mg/mL in DMEM with 10% fetal calf serum, antibiotic-free; Sigma-Aldrich, St. 
Louis, MO, USA) was added to each well and the plates were further incubated for 4 h. The crystal 
was dissolved in 100 µL lysis buffer (16 µL glycine buffer (0.1M gylcine, 0.1M NaCl, pH 10.5) and 
84 µL DMSO)  for 10 min. The absorbance was measured at a wavelength of 570 nm using a 
microplate reader (SpectraMax 190, Molecular Devices, MDS, Sunnyvale, CA, USA). For 
nomalization, absolute absorbance was divided by the absorbance of wells with All Stars negative 
control siRNA (Qiagen, Hilden, Germany).  
Proliferation assays. Cell proliferation capacity of siRNA-transfected cultures was determined by 
seeding 125,000 PC3 cells in series of 6-well culture dishes and cultivating them for several days. 
PC3 cells were counted every 24 hours with a coulter counter. For each culture, the cell number at 
each time point reflects the average of data from three dishes.  
Western blot analysis. Cultured cells were lysed in TNN buffer (25mM Tris–HCl pH 7.2, 500mM 
sodium chloride, 10% glycerol, 1% NP-40, 10mM sodium fluoride, 1mM Na3VO4, 1mM PMSF, 
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1mM dithiothreitol, 10 mg/ml aprotinin). Protein extracts (50 mg) were run on 8–15% 
polyacrylamide gels, transferred to nitrocellulose membranes and visualised by immunoblotting 
with the following antibodies: anti-KPNA2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA, 
no. 6917), anti-tubulin-alpha (anti-rat antibody; kindly provided by Wilhelm Krek, Institute of Cell 
Biology, ETH Zurich, Switzerland),  and anti-PARP (BD Biosciences, Allschwil, Switzerland, 
556362). As positive control for the induction of apoptosis, Staurosporine solution (Sigma-Aldrich 
Chemie GmbH, Buchs, Switzerland, no. S6942, final concentration 5 µm) was added to the cells 24 
hours prior to lysation.  
Analysis of apoptosis by propidium iodide staining and flow cytometry. The propidium iodide 
(PI) flow cytometric assay has been widely used for the evaluation of apoptosis. It is based on the 
principle that apoptotic cells are characterized by DNA fragmentation and, consequently, loss of 
nuclear DNA content. Use of a fluorochrome, such as PI, that is capable of binding and labeling 
DNA makes it possible to obtain a rapid and precise evaluation of cellular DNA content by flow 
cytometric analysis, and subsequent identification of hypodiploid cells. PC3 cells were transfected 
with negative control siRNA or pooled siRNA against KPNA2. For subG1 DNA content analysis 
and calculation of the mitotic index, PC3 cells were processed for flow cytometric analysis (FACS) 
72 hours after transfection as described (17). Fluorescence intensities of the samples (n=10,000) 
were measured, using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA).  
Statistical analyses. To study statistical associations between clinicopathological and 
immunohistochemical data, contingency table analysis and two-sided Fisher’s exact tests were used. 
For the comparison of two independent samples the non-parametric Mann-Whitney test was 
calculated. Time to PSA recurrence (cutoff ≥ 0.1 ng/ml) was selected as clinical end point. Only 
patients with primary PCa undergoing radical prostatectomy and reaching the PSA nadir (<0.1 
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ng/ml) postoperatively were used for survival analysis. Univariate Cox regression analysis was used 
to evaluate statistical association between clinicopathological/immunohistochemical data and 
recurrence-free survival (RFS). RFS curves were calculated using the Kaplan-Meier method with 
significance evaluated by two-sided log-rank statistics. Patients were censored at the time of their 
last tumor-free clinical follow-up visit. A stepwise multivariable Cox regression model was 
adjusted, testing the independent prognostic relevance of KPNA2 immunoreactivity. The 
proportionality assumption for all variables was assessed with log-negative-log survival distribution 
functions. SPSS version 17.0 (SPSS, Chicago, IL, USA) was used for statistical analyses. P-values 
<0.05 were considered significant. In case of multiple tests the Bonferroni-Holm procedure was 
applied. 
Statistical considerations regarding sample size. In our training population, KPNA2 expression 
could be observed in 140 of 341 (41.1%) prostatectomy specimens. We further estimated that the 
occurrence of KPNA2 expression doubles the risk of PSA recurrence during follow up, resulting in 
a hazard ratio of 2.0. Supplemental Figure 2 depicts the estimation of statistical power versus total 
sample size N for different hazard ratios. Accordingly, the available sample size of 341 analyzable 
patients would be sufficient to detect a difference concerning PSA recurrence with a significance of 
p<0.05 and a power of almost 100%. Calculations were performed using the respective models of 
the PASS 2008 software (NCSS, Kaysville, UT). 
 
 
RESULTS 
Zurich TMA (training cohort).  
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Descriptive and univariate analysis. KPNA2 and NBS1 protein expression in non-malignant and 
PCa tissue samples was investigated by immunohistochemical analysis of the Zurich TMA 
containing 468 specimens from patients with benign or malignant prostatic disease.  A total of 455 
(97.2%) could be evaluated for KPNA2 and 440 (94.0%) for NBS1 immunostaining. Representative 
KPNA2 and NBS1 staining patterns are summarized in Figures 1A-1D. In general, KPNA2 and 
NBS1 expression in at least 0.1% of nuclei was detectable in 193 of 455 (42.4%) and in 391 of 440 
(88.9%) of analyzable cases, respectively (Figure 2A and Supplemental Figure 3). Nuclear KPNA2 
immunoreactivity continuously increased from prostatic hyperplasia to organ-confined PCa to 
metastatic and castration resistant disease (Figure 2A; p<0.001). Regarding NBS1 expression, 
malignant prostate tissues showed a significantly (p<0.001) higher expression compared to prostatic 
hyperplasia (Supplemental Figure 3). For the different types of metastases (lymph node, bone, lung, 
bladder), differences in expression levels of KPNA2 and NBS1 were not detectable (data not 
shown). Regarding all tissue samples on the Zurich TMA, positive nuclear KPNA2 immunostaining 
was significantly associated with positiv nuclear NBS1 immunostaining (p<0.001; Figure 2B). In 
the subgroup of prostatectomy specimens the same significant association was found (p=0.004, 
Figure 2C). Clinicopathological and immunohistochemical data are summarized in Supplemental 
Table 1. 
 Clinicopathological characteristics of the prostatectomy patients were correlated with KPNA2 and 
NBS1 expression (Table 1A). In primary PCas, nuclear KPNA2 and NBS1 expression was not 
associated with any of the parameters (age at diagnosis, Gleason score, tumor stage, nodal status, 
surgical margin status, preoperative PSA level).  
Univariate Cox regression analysis (Table 2A) and log-rank statistics revealed, that KPNA2 
expression was highly associated with shorter RFS (p=0.001, Figure 2D). The estimated five year 
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recurrence-free survival rate of KPNA2 positive cases was 0.607 (standard error 0.055), whereas 
patients with KPNA2 negative tumors showed a recurrence-free survival rate of 0.794 (standard 
error 0.034). In a subgroup analysis of patients with moderately differentiated tumors (e.g. Gleason 
7), nuclear KPNA2 staining was associated with shorter RFS times (p<0.001; data not shown). 
NBS1 immunostaining was not associated with shorter RFS (p=0.175). Besides, higher Gleason 
scores (>7), increased tumor stage (pT3a-pT4), positive surgical margin status, and increased 
preoperative PSA levels (≥10ng/ml) were significantly associated with shorter RFS time (p<0.01, 
Table 2A).  
Multivariate analysis. In a multivariate analysis, a Cox regression model was developed for 
assessment of the RFS rate. Characteristics of variables are shown in Table 3A. Because of model 
assumptions (noninformative censoring, proportional hazards), only nuclear KPNA2 expression, 
Gleason score, tumor stage, surgical margin status and preoperative PSA levels were considered. 
All variables, including nuclear KPNA2 expression (p=0.002) remained significant. The hazard 
ratio for KPNA2 expression was 2.129 (95% confidence interval 1.332-3.403). 
 
Regensburg TMA (testing cohort). 
Descriptive and univariate analysis. KPNA2 protein expression was investigated by 
immunohistochemical analysis of a Regensburg TMA containing 330 prostatectomy specimens 
from patients with PCa. A total of 237 cores (71.8%) could be evaluated for KPNA2. Applying the 
same criteria for positive KPNA2 immunoreactivity as established for the training cohort, KPNA2 
expression was detected in 124 of 237 (52.3%) analyzable samples (Supplemental Table 1). In 
primary PCas, nuclear KPNA2 expression was not associated with any of the parameters (Table 
1B). In Kaplan-Meier analysis, KPNA2 expression was significantly associated with shorter RFS 
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(Figure 2E, Table 2B). Five year recurrence-free survival rate were 0.769 (standard error 0.066) and 
0.589 (standard error 0.050) for KPNA2 negative and positive cases, respectively. Besides, only 
increased tumor stage (p=0.003) was significantly associated with shorter RFS time.  
Multivariate analysis. To further verify the prognostic value of the KPNA2 assay, another Cox 
regression model was developed (Table 3B). Only nuclear KPNA2 expression (p=0.005) remained 
significant. The hazard ratio for KPNA2 expression was 2.653 (95% confidence interval 1.340-
5.253). 
 
MTT and proliferation assays. SiRNA technologies were used to inhibit KPNA2 expression, and 
the effect of this inhibition on cellular function was determined. PC3 and LNCaP PCa cells were 
reverse and transiently transfected with siRNAs against KPNA2. To determine whether inhibition 
of expression had biological relevance, a cell proliferation assay was performed on the presence of 
controls and KPNA2 siRNAs. PC3 cell proliferation and viability was significantly reduced in cells 
where KPNA2 expression was inhibited (Figure 3A). Results of the MTT assay could be confirmed 
in a second experiment, using pooled and non-pooled siRNAs (Figure 3F). In contrast to the 
androgen-refractory cell line PC3, siRNA mediated KPNA2 knockdown did not have any 
significant effect on the viability the hormone-dependent cell line LNCaP (Figure 3E). These 
findings suggest that KPNA2 may be important for the proliferation of androgen-independent PCa 
cells. In order to show the efficency of our knock down experiments, PC3 and LNCaP cells were 
transfected with siRNAs against KPNA2 (pooled and non-pooled) and controls, and whole cell 
lysats were prepared and processed for immunoblotting with KPNA2 antibody (Figure 3B). 
Specificity of the KPNA2 antibody was determined by immunostaining of paraffin embedded cell 
pellets (Figure 3C and 3D) with KPNA2 antibody. KPNA2 knockdown did not induce apoptosis. In 
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detail, knockdown of KPNA2 did not induce poly(ADP-ribose) polymerase (PARP) cleavage 
(Figure 4A) as marker for apoptosis. As positive control, PC3 cells, treated with staurosporin, 
showed cleaved PARP (Figure 4B). No significantly increased subG1 fraction could be found by 
FACS analysis (Figure 4C). However, knockdown of KPNA2 decreased the number of actively 
dividing cells as compared to control cells (Figure 4D).  
Accordingly, KPNA2 expression may be involved in androgen receptor-mediated proliferation in 
PCa. To address this question, expression of the cytoplasmic chemokine (C-X-C motif) receptor 4 
(CXCR4) in KPNA2 negative versus positive PCa samples was investigated (Figures 4E-4F). 
Cytoplasmic CXCR4 expression was significantly increased in KPNA2 positive PCa samples. 
 
 
DISCUSSION 
In the present study KPNA2 was significantly upregulated in adenocarcinomas of the prostate, 
especially in metastatic and castration-resistant PCa. Moreover, positive nuclear KPNA2 
immunoreactivity was identified as a novel predictor of biochemical recurrence after radical 
prostatectomy, which was independent of the well-established predictive factors preoperative PSA 
value, Gleason score, tumor stage and surgical margin status. These results were confirmed in a 
second independent testing cohort. The classical markers high Gleason score, high tumor stage, 
positive surgical margins, and increased preoperative PSA levels were relevant for the recurrence 
probability as well. 
Karyopherin alpha 2 (KPNA2) is a member of the karyopherin (importin) family, which plays a 
central role in nucleocytoplasmic transport. It acts as an adaptor in the nuclear import of 
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macromolecules by binding cargoproteins, which contain a classical nuclear localization signal 
(18). Linking a cargoprotein and Karyopherin beta, KPNA2 initiates the transport through the 
nuclear core complex (19). In particular, KPNA2 is a major adaptor for the nuclear localization of 
NBS1 (Nijmegen breakage syndrome 1), a key regulator of the MRE11/RAD50/NBS1 (MRN) 
complex (20). This complex plays an important role in the early processing of double strand breaks 
(DSB) (21). NBS1 has two important roles based on its subcellular localization, with KPNA2 being 
the major effector to determine the subcellular localization of NBS1. In the nucleus, NBS1 acts as 
tumor suppressor involved in DNA DSB repair, maintaining genome stability. In the cytoplasm, 
however, NBS1 provides an oncogenic role which promotes tumorigenesis through binding and 
activation of the phosphatidylinositol 3-kinase/AKT pathway (22).   
Another recently described KPNA2 mediated transport-mechanism is the nuclear import of the 
androgen receptor (AR). During the development of PCa, cell survival depends primarily on the AR 
(23). Binding of the active androgen dihydrotestosterone to the AR leads to its KPNA2 dependent 
translocation into the nucleus, where it activates the transcription of a wide range of target genes 
(24). Considering this, KPNA2 overexpression might be an indicator for increased translocation of 
the AR and be therefore associated with highly proliferative and hormone refractory PCa. 
Accordingly, in this study nuclear KPNA2 immunoreactivity continuously increased from prostatic 
hyperplasia to organ-confined PCa to metastatic and castration resistant disease (Figure 2A).  
Furthermore, expression of the cytoplasmic chemokine (C-X-C motif) receptor 4 (CXCR4) in 
KPNA2 negative vs. positive PCa samples was investigated (Figures 4E-4F). Carver et al. have 
recently shown that CXCR4, a candidate gene strongly associated with cell migration, was 
upregulated in the presence of ERG overexpression. Thus, androgens may induce CXCR4 through 
ERG factor expression in TMPRSS2-ERG fusion-positive PCa cells (25). In our study, CXCR4 
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expression was significantly increased in KPNA2 positive PCa, supporting our hypothesis that 
KPNA2 expression may be involved in androgen receptor-mediated proliferation in PCa. 
Previous investigations could prove KPNA2 overexpression in other solid tumors like melanoma 
and breast cancer and also demonstrated an association with shorter survival rates (11, 13, 26). 
Recently, KPNA2 expression has been confirmed in a randomized patient cohort of high-risk breast 
cancer patients. KPNA2 expression was an independent negative prognostic factor for event-free 
and overall survival (12). Considering this last clinical trial, the data confirmed that KPNA2 
positivity defines an aggressive breast cancer phenotype.  
The preliminary functional data of the present study shows a reduced cell viability of PC3 PCa cells 
upon KPNA2 knock down, suggesting that KPNA2 is essential for PCa cellular function. KPNA2 
knockdown did not induce apoptosis but reduced cell proliferation and viability of androgen-
independent PC3 cells. This clearly merits further study. Van der Watt et al. (27) examined the 
expression of karyopherins, exportin 1 (XPO1), Karyopherin beta 1 (KPNB1) and KPNA2, in 
cervical tissue and cell lines. Individual siRNAs were used to investigate the functional significance 
of these proteins. They also found KPNA2 overexpressed in cervical cancer compared to normal 
tissue, which is concordant to our PCa data. Also, inhibition of XPO1 and KPNB1 expression 
induced cancer cell death, whereas siRNA-mediated KPNA2 knock down had no significant effect 
(27). The partially different cellular responses to the inhibition of KPNA2 in prostate and cervical 
cancer cell lines could be due to tissue-specific tumor etiologies and also warrant further study. 
Molecular tissue biomarkers play an increasingly important role in clinical oncology. They could 
help to detect the disease at an early stage, guide treatment decisions, and help to identify 
subpopulations of patients who are most likely to benefit from a specific therapy (28). However, 
prognostic evaluation of a specific cancer patient by analysis of cancer tissue for protein expression 
 American Association for Cancer Research Copyright © 2011 
 on February 3, 2011clincancerres.aacrjournals.orgDownloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on January 10, 2011; DOI:10.1158/1078-0432.CCR-10-0081
Clinical Cancer Research - Imaging & Diagnosis 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.  
Copyright © 2011 American Association for Cancer Research 
remains challenging. Up to now, none of the published tissue biomarkers for PCa has found its way 
into clinical practice. The description of KPNA2 as an independent marker of PSA relapse in two 
independent cohorts of PCa clearly constitutes KPNA2 expression as strong biomarker. Further 
studies have to clarify, if KPNA2 immunohistochemistry can also aid in the discrimination of 
insignificant and significant PCa at the time of the positive biopsy, which we speculate is likely.  
In summary, we found KPNA2 overexpressed during malignant tumor progression of PCa. 
Moreover, KPNA2 expression was associated with shortened recurrence-free survival time in 
univariate and multivariate analyses in two independent patient cohorts treated by radical 
prostatectomy. This raises the possibility for a better individualized risk stratification to optimize 
therapy. The clinical application of these findings has to be investigated in further studies using 
prostate biopsy material. 
 
 
 
 
FIGURE LEGENDS 
Figures 1A – 1D. Immunohistochemical expression of KPNA2 (A & C) and NBS1 (B & D) in 
hyperplastic and malignant prostate tissue. A, B: Hyperplastic prostate tissue without nuclear 
KPNA2 or NBS1 immunoreactivity. C, D: High grade prostate cancer tissue with strong nuclear 
KPNA2 and NBS1 expression. Original magnification: 400×; Magnification bars: 20 µM. 
Figures 2A-E. A: Cumulative bar chart representing nuclear immunoreactivity for KPNA2 in 
different tissue types (BPH: benign prostate hyperplasia; ADCA RPE: organ-confined prostate 
cancer; MTS: prostate cancer metastasis; CRPC: castration-resistant prostate cancer). B-C: 
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Cumulative bar chart representing the correlation between nuclear immunorectivity of NBS1 and 
KPNA2 in all tissue samples (B) and in the subgroup of prostatectomy specimens (C). D-E: 
Kaplan–Meyer curves regarding recurrence-free survival of prostate cancer patients with no 
KPNA2 expression versus patients with positive KPNA2 expression in the training (D) and the 
testing cohort (E).  
Figures 3A-3F.  A: Boxplots showing results of the MTT assay for PC3 cells. Four specific 
KPNA2 and NBS1 siRNAs were pooled (final concentration 0.05 µM) and all values were 
normalized to AllStars negative control siRNA (Qiagen). B: Western blot analysis of PC3 and 
LNCaP cells after control knockdown (All Stars negative control) or knockdown of KPNA2. Blots 
were probed with antibodies against KPNA2 and alpha-tubulin. C & D: Immunohistochemical 
KPNA2 expression in Paraffin embedded cell pellets of PC3 (C) and LNCaP cells (D). Original 
magnification: 400×; Magnification bars: 20 µM. E & F: Boxplots showing results of the MTT 
assay using LNCaP and PC3 cells. Four specific KPNA2 siRNAs were either pooled or used 
separately at a final concentration of 0.05 µM. All values were normalized to AllStars negative 
control siRNA (Qiagen).  
Figures 4A-4F. A: Western blot analysis showing KPNA2, poly(ADP-ribose) polymerase (PARP), 
and α-Tubulin levels after KPNA2 knockdown. Knockdown of KPNA2 did not result in PARP 
cleavage. B: Control experiment showing cleaved PARP after staurosporine treatment of PC3 cells.  
C: FACS assay showing the subG1 fraction in PC3 cells with KPNA2 knock-down compared with 
control cells. PC3 cells were transfected with control siRNA (blue) or pooled siRNAs against 
KPNA2 (grey) and analyzed for subG1 DNA content, 72 hours after transfection by fluorescence-
activated cell sorting. Data are represented as mean % ± standard deviation, n=2. D: PC3 cells were 
either transfected with control siRNA (blue) or pooled siRNAs against KPNA2 (grey), and cell 
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numbers were determined over the indicated time period. An average of three independent 
experiments is shown. Data are represented as normalized mean cell numbers (± standard 
deviation). E: Cumulative bar charts representing the correlation between CXCR4 and KPNA2 
immunorectivity in the subgroup of prostatectomy specimens, respectively. F: Prostate cancer 
tissue of a radical prostatectomy specimen with strong immunohistochemical CXCR4 expression 
(cytoplasmic intensity score 3+). Original magnification: 200×; magnification bars: 20 µM; inset: 
negative CXCR4 immunoreactivity. 
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Table 1. Clinicopathological characteristics in relation to KPNA2 and NBS1 immunoreactivity in radical prostatectomy specimens 
A: Zurich tissue-microarray
negative positive p
* negative positive p
*
Age at diagnosis (grouped) < 64 years 83 64 0.367 14 129 0.428
≥ 64 years 114 70 13 165
Gleason score (grouped) 5-6 38 18 0.352 6 45 0.515
7 114 85 14 183
8-10 48 36 7 75
Tumor stage (grouped) pT2a-c 134 83 0.332 23 186 0.053
pT3a-b 59 50 4 104
pT4 6 6 0 12
Nodal status pN0 154 111 0.799 23 238 0.616
pN1 10 6 0 14
Surgical margin status negative 134 86 0.292 19 191 0.399
positive 62 52 7 108
Preoperative PSA levels < 10 ng/mL 81 52 0.906 10 120 1.000
≥ 10 ng/mL 99 66 13 146
B: Regensburg tissue-microarray
negative positive p
Age at diagnosis (grouped) < 64 years 58 70 0.437
*
≥ 64 years 55 54
Gleason score (grouped) 5-6 38 45 0.675
**
7 23 27
8-10 23 36
Tumor stage (grouped) pT2a-c 46 44 0.348
**
pT3a-b 64 79
pT4 3 1
Nodal status pN0 92 97 0.491
*
pN1 17 24
Surgical margin status negative 69 70 0.510
*
positive 44 54
Preoperative PSA levels < 10 ng/mL 54 46 0.080
*
≥ 10 ng/mL 51 71
*
 Fisher's exact test or 
**
 Pearson Chi-Square test, two-sided; bold face representing p<0.05.
Variable Characteristics
Nuclear KPNA2 immunreactivity
NBS1 nuclear immunoreactivityNuclear KPNA2 immunreactivity
Variable Characteristics
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Table 2. Univariate Cox regression analysis
A: Zurich tissue-microarray
HR 95% CI P *
Age at diagnosis 1.006
0.964-
1.050
0.772
Gleason score (grouped) 5-7 vs  8-10 2.972
1.823-
4.844
<0.001
Tumors stage (grouped) pT2a-c vs  pT3a-4 2.336
1.625-
3.356
<0.001
Surgical margin status negative vs  positive 3.268
2.069-
5.161
<0.001
Preoperative PSA level
< 10 ng/mL vs  ≥ 10 
ng/mL
2.317
1.432-
3.748
0.001
Nuclear KPNA2 
immunoreactivity
0% vs  >0% 2.075
1.314-
3.277
0.002
Nuclear NBS1 
immunoreactivity
0% vs  >0% 2.013
0.732-
5.538
0.175
B: Regensburg tissue-microarray
HR 95% CI P *
Age at diagnosis 0.978
0.942-
1.016
0.257
Gleason score (grouped) 5-7 vs  8-10 1.400
0.816-
2.403
0.222
Tumors stage (grouped) pT2a-c vs  pT3a-4 2.074
1.279-
3.362
0.003
Surgical margin status negative vs  positive 0.114
0.717-
1.807
0.582
Preoperative PSA level
< 10 ng/mL vs  ≥ 10 
ng/mL
1.320
0.818-
2.132
0.255
Nuclear KPNA2 
immunoreactivity
0% vs  >0% 1.703
1.013-
2.864
0.044
*
 P-values <0.05 are marked in bold.
vs , versus.
CI, confidence interval.
HR, hazard ratio.
Variable Characteristics
Recurrence-free survival
Variable Characteristics
Recurrence-free survival
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Table 3. Multivariate Cox regression analysis
A: Zurich tissue microarray
HR 95% CI P 
*
Gleason score (grouped) 5-7 vs  8-10 2.119
1.250-
3.590
0.005
Tumors stage (grouped) pT2a-c vs pT3a-pT4 2.016
12.38-
3.284
0.005
Surgical margin status negative vs  positive 2.519
1.558-
4.071
<0.001
Preoperative PSA level
< 10 ng/mL vs  ≥ 10 
ng/mL
1.954
1.150-
3.321
0.013
Nuclear KPNA2 
immunoreactivity
0% vs  >0% 2.129
1.332-
3.403
0.002
B: Regensburg tissue microarray
HR 95% CI P 
*
Gleason score (grouped) 5-7 vs  8-10 0.851
0.425-
1.706
0.650
Tumors stage (grouped) pT2a-c vs pT3a-pT4 1.970
0.926-
4.192
0.078
Surgical margin status negative vs  positive 0.826
0.418-
1.633
0.583
Preoperative PSA level
< 10 ng/mL vs  ≥ 10 
ng/mL
1.674
0.849-
3.304
0.137
Nuclear KPNA2 
immunoreactivity
0% vs  >0% 2.653
1.340-
5.253
0.005
*
 P-values <0.05 are marked in bold.
vs, versus.
CI, confidence interval.
HR, hazard ratio.
Variable Characteristics
Recurrence-free survival
Variable Characteristics
Recurrence-free survival
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A B Benign
hyperplasia
C D Prostate
cancer
KPNA2 NBS1
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